Eloralintide vs Melanotan II
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
EloralintideSexual Health & Libido
Melanotan II- Summary
- Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
- Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that stimulates melanin production (skin tanning), suppresses appetite, and enhances sexual function. It is not FDA-approved and has significant safety concerns including mole changes and cardiovascular effects.
- Half-Life
- ~7 days (estimated, long-acting design)
- 1–2 hours
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- Under investigation in Phase 1/2 trials
- 0.25–0.5 mg
- Frequency
- Once weekly
- Once daily
- Key Benefits
- Once-weekly dosing (vs multiple daily injections for pramlintide)
- Appetite suppression via central amylin receptor activation
- Reduction in post-meal glucagon secretion
- Complementary mechanism to GLP-1 agonists for combination therapy
- Slows gastric emptying for prolonged satiety
- Potential additive weight loss when combined with GLP-1 agents
- Promotes skin tanning and melanin production
- Reduces UV exposure needed to tan
- Enhances libido and sexual function
- May suppress appetite
- Faster, deeper tan development
- Longer-lasting tan maintenance
- Potential photoprotective effects
- Side Effects
- Nausea
- Vomiting
- Decreased appetite
- Injection site reactions
- +1 more
- Nausea (very common, especially in first days)
- Facial flushing
- Spontaneous erections in men
- Darkening or changes in existing moles (monitor closely)
- +3 more
- Stacks With
- —
- —